ATE370145T1 - Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten - Google Patents

Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten

Info

Publication number
ATE370145T1
ATE370145T1 AT03718092T AT03718092T ATE370145T1 AT E370145 T1 ATE370145 T1 AT E370145T1 AT 03718092 T AT03718092 T AT 03718092T AT 03718092 T AT03718092 T AT 03718092T AT E370145 T1 ATE370145 T1 AT E370145T1
Authority
AT
Austria
Prior art keywords
sub
pharmaceutical compositions
compositions containing
based compounds
containing same
Prior art date
Application number
AT03718092T
Other languages
English (en)
Inventor
Makonen Belema
Amy Bunker
Van Nguyen
Francis Beaulieu
Carl Ouellet
Anne Marinier
Stephan Roy
Xuejie Yang
Yuping Qiu
Yunhui Zhang
Alain Martel
Christopher Zusi
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE370145T1 publication Critical patent/ATE370145T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03718092T 2002-04-03 2003-03-27 Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten ATE370145T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36969802P 2002-04-03 2002-04-03

Publications (1)

Publication Number Publication Date
ATE370145T1 true ATE370145T1 (de) 2007-09-15

Family

ID=28791986

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03718092T ATE370145T1 (de) 2002-04-03 2003-03-27 Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten

Country Status (7)

Country Link
US (1) US6933294B2 (de)
EP (1) EP1490371B1 (de)
AT (1) ATE370145T1 (de)
AU (1) AU2003222106A1 (de)
DE (1) DE60315615T2 (de)
ES (1) ES2291628T3 (de)
WO (1) WO2003084959A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
ITMI20032069A1 (it) * 2003-10-23 2005-04-24 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procedimento per la preparazione di derivati benzilmidazolici.
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US7456194B2 (en) * 2004-11-12 2008-11-25 Bristol-Myers Squibb Company Imidazo-fused oxazolo [4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2006053166A1 (en) * 2004-11-12 2006-05-18 Bristol-Myers Squibb Company 8h-imidazo[4,5-d]thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US20060167057A1 (en) * 2004-11-16 2006-07-27 Xianqi Kong Compounds for the treatment of CNS and amyloid associated diseases
US7683171B2 (en) * 2005-02-04 2010-03-23 Bristol-Myers Squibb Company 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7737279B2 (en) * 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
AU2006266028B2 (en) 2005-06-30 2012-03-15 Smithkline Beecham Corporation Chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
PL2448938T3 (pl) 2009-06-29 2014-11-28 Incyte Holdings Corp Pirymidynony jako inhibitory PI3K
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
WO2011075643A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2558463A1 (de) 2010-04-14 2013-02-20 Incyte Corporation Kondensierte derivate als i3-hemmer
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
FR2962438B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102131612B1 (ko) 2011-09-02 2020-07-08 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CN104163788A (zh) * 2014-07-07 2014-11-26 湖南华腾制药有限公司 一种吡啶衍生物的制备方法
MA41607B1 (fr) 2015-02-27 2021-01-29 Incyte Corp Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2023203254A2 (en) * 2022-04-22 2023-10-26 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182386A (en) * 1991-08-27 1993-01-26 Neurogen Corporation Certain imidazoquinoxalinones; a new class of gaba brain receptor ligands
US5243012A (en) 1992-06-10 1993-09-07 Miles Inc. Polyurea coating compositions having improved pot lives
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
FR2707645B1 (fr) * 1993-07-16 1995-08-11 Rhone Poulenc Rorer Sa Dérivés d'imidazo[1,2-a]pirazine-4-one, leur préparation et les médicaments les contenant.
FR2722789B1 (fr) * 1994-07-20 1996-08-23 Rhone Poulenc Rorer Sa Derives d'acide imidazo (1,2-a)indeno(1,2-e) pyrazine-2-carboxylique, leur preparation et les medicaments les contenant
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体

Also Published As

Publication number Publication date
EP1490371A4 (de) 2006-03-22
EP1490371A1 (de) 2004-12-29
DE60315615T2 (de) 2008-10-02
DE60315615D1 (de) 2007-09-27
US20040058930A1 (en) 2004-03-25
ES2291628T3 (es) 2008-03-01
AU2003222106A1 (en) 2003-10-20
WO2003084959A1 (en) 2003-10-16
EP1490371B1 (de) 2007-08-15
US6933294B2 (en) 2005-08-23

Similar Documents

Publication Publication Date Title
ATE370145T1 (de) Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
YU11997A (sh) Laktamski derivati i njihove farmaceutske kompozicije
ME00411B (me) Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma
ATE503746T1 (de) Neue imidazolidinderivate
NO20050065L (no) Kjemiske forbindelser
DE69903923T2 (de) Bizyklische pyrrolderivate als mcp-1 inhibitoren
EA200401613A1 (ru) Лекарственное средство для лечения рака
AP1902A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
NO20060219L (no) Forbindelser
IS6309A (is) Kínasólínafleiður
BRPI0610312B8 (pt) dispositivo de assistência à caminhada
HRP20070510T3 (en) Benzimidazole derivative and its use as a ii receptor antagonist
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE280763T1 (de) Matrix-metalloproteinase-hemmer
DE60118225D1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
HUP0201953A2 (hu) Benzolszármazékok, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
NO20054787D0 (no) Indenderivater som farmasotiske midler
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
UY27979A1 (es) Indoles sustituidos en posición 2,4
DE602004020730D1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
ATE525366T1 (de) Benzoxazolderivate und pharmazeutische zubereitungen die diese enthalten
WO2005097100A3 (en) Antibacterial agents
IS2194B (is) Efnasambönd sem innihalda píperasín sem eru gagnleg til meðhöndlunar á sársauka

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1490371

Country of ref document: EP

REN Ceased due to non-payment of the annual fee